SRPT — Sarepta Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 873303 ·
Last close
$14.77
Market Cap
$1.58B
52W High
$24.68
52W Low
$14.59
ADV30
2,499,610
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 381,351,000 | 192,839,000 | -9,040,000 | -28,461,000 | 3,166,066,000 | 472,760,000 | 1,637,213,000 |
| Jun 2026 | 401,251,000 | 251,866,000 | 52,291,000 | -4,890,000 | 3,188,512,000 | 571,148,000 | 1,660,714,000 |
| Mar 2026 | 730,803,000 | 622,035,000 | 358,433,000 | 330,959,000 | 3,178,934,000 | 464,450,000 | 1,673,832,000 |
| Dec 2025 | 442,934,000 | 44,226,000 | -410,084,000 | -282,847,000 | 3,349,703,000 | 801,282,000 | 2,209,081,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$111,008,000
Investing CF
$100,845,000
Financing CF
$-156,757,000
CapEx
$-36,037,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.90
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,550,915,000
Inventory
$904,273,000
Receivables
$438,814,000
ST Investments
$217,341,000
EBIT TTM
$-59,290,000
Pretax Income TTM
$-130,920,000
Interest Exp TTM
$71,630,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,956,338,944
EBITDA
$23,756,000
Free Cash Flow
$109,313,752
Enterprise Value
$2,111,220,864
Total Cash
$878,776,000
Total Debt
$1,079,053,952
Shares Out
107,235,848
Trailing EPS
$0.02
Book Value
$14.26
ROE
-8.0%
ROA
-0.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,198,237,000 | -657,772,000 | -713,410,000 | 3,349,703,000 | 2,209,081,000 | 1,140,622,000 | -205,479,000 |
| Dec 2024 | 1,901,979,000 | 218,081,000 | 235,239,000 | 3,963,173,000 | 2,435,431,000 | 1,527,742,000 | -205,787,000 |
| Dec 2023 | 1,243,336,000 | -267,824,000 | -535,977,000 | 3,264,576,000 | 2,405,239,000 | 859,337,000 | -500,993,000 |
| Dec 2022 | 933,013,000 | -536,201,000 | -703,488,000 | 3,128,366,000 | 2,743,416,000 | 384,950,000 | -325,346,000 |
TTM Snapshot
Revenues TTM
$1,974,344,000
NetIncome TTM
$-136,725,000
OpCashFlow TTM
—
Assets (Latest)
$3,188,512,000
Forward EPS
$2.33
Max Pain — expiry 2027-12-17
max pain strike: $7.50 · spot: $14.53 · call oi: 0 · put oi: 1,747
Expected Move to 2027-12-17:
±$8.90
(61.25%) —
implied range
$5.63 –
$23.43
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc. | $1.58B | $12.20 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.59B | $69.99 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.56B | $14.24 | — |
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
News headlines (Yahoo Finance, 1h cache)
DraftKings downgraded, Sarepta upgraded: Wall Street's top analyst calls
2026-11-10 14:46 · Yahoo
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
2026-11-09 22:12 · Yahoo
Learn Why The Bull Case For Sarepta Therapeutics Stock Could Change Following Raised Revenue Guidance
2026-11-07 11:14 · Yahoo
Sarepta (SRPT) Q3 2026 Earnings Call Transcript
2026-11-06 16:14 · Yahoo
Sarepta Therapeutics Q3 Earnings Call Highlights
2026-11-06 09:14 · Yahoo
Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates
2026-11-06 00:00 · Yahoo
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
2026-11-05 23:30 · Yahoo
Sarepta Therapeutics: Q3 Earnings Snapshot
2026-11-05 22:09 · Yahoo
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
2026-11-05 21:05 · Yahoo
Sarepta Therapeutics Inc (SRPT) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised ...
2026-11-06 11:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.